Does a Prolactinoma Cause Bone Loss and Osteoporosis?
At a Glance
A prolactinoma can cause bone loss and osteoporosis by lowering essential sex hormones like estrogen and testosterone. Treating the tumor with medication usually restores these hormones and helps reverse bone density loss over time. A baseline DEXA scan is highly recommended.
In this answer
4 sections
High prolactin levels from a prolactinoma can silently lead to bone density loss and osteoporosis. This happens because prolactin acts as a major disruptor to the system that produces your body’s sex hormones. When prolactin remains high for a long period, it suppresses the normal release of gonadotropin-releasing hormone (GnRH) in your brain [1][2]. This suppression creates a domino effect: your brain sends fewer signals to your reproductive system, causing a sharp drop in estrogen for women and testosterone for men [1][3]. Because these sex hormones are critical for maintaining healthy, strong bones, their absence causes the body to break down bone tissue faster than it can rebuild it, leading to decreased bone mineral density [4].
Why Men Face a Higher Risk
While both men and women can experience bone loss from hyperprolactinemia, men are considered to be at a particularly high risk [4][5]. Prolactinomas in men often go undiagnosed for much longer than in women, largely because the symptoms of low testosterone—such as fatigue, low libido, and erectile dysfunction—can be vague or attributed to stress and aging [3][4]. As a result, men may endure years of untreated low testosterone (hypogonadism), giving bone loss a significant head start [4]. In fact, bone impairment is often seen as a direct reflection of how severe and long-lasting the disease has been prior to diagnosis [4].
Do You Need a DEXA Scan?
A DEXA scan (Dual-Energy X-ray Absorptiometry) is the gold standard imaging test used to measure bone density and diagnose osteoporosis [6][7]. Because bone loss doesn’t cause pain or obvious symptoms until a fracture occurs, you cannot feel your bones getting weaker.
If you have been diagnosed with a prolactinoma, clinical vigilance regarding your bone health is essential [8][9]. A baseline DEXA scan is often recommended to assess whether the prolactinoma has already caused bone impairment, particularly for:
- Men with prolactinomas, given their higher likelihood of long-standing, undiagnosed low testosterone [4][9].
- Women who have experienced prolonged periods without a menstrual cycle (amenorrhea) [10].
- Anyone experiencing unexplained bone pain or who has suffered a fracture from a minor injury [8].
Recommended Frequency for Scans
While there is no single, universal timeline for repeat DEXA scans specifically for prolactinoma patients, monitoring usually depends on your baseline results and whether your hormone levels are recovering [6][11].
- Initial Assessment: You should ask your doctor for a baseline DEXA scan to establish your starting bone density, especially if you have had symptoms of low sex hormones for a long time [12][13].
- Follow-up Scans: If your baseline scan shows normal bone density and treatment successfully restores your testosterone or estrogen levels, you may not need another scan for several years. However, if you are diagnosed with osteopenia (low bone mass) or osteoporosis, or if your sex hormones remain persistently low, your doctor will likely recommend a repeat DEXA scan every 1 to 2 years to closely track your progress [14][11].
Treatment and Reversing Bone Loss
The bone loss caused by a prolactinoma is often highly treatable. By taking dopamine agonist medications (such as cabergoline or bromocriptine), you can effectively shrink the tumor and lower your prolactin levels [15][16]. Once prolactin drops back to a normal range, the reproductive system typically “wakes up” and resumes producing healthy levels of estrogen and testosterone [17][18]. Over time—often months to years, as bone remodeling is a slow process—restoring these essential hormones helps stabilize and often improves your bone mineral density [19][20].
When Further Treatment is Needed
In some cases, especially for men with very large tumors that have permanently damaged the pituitary stalk or tissue, dopamine agonists alone may not fully restore testosterone or estrogen levels. If your sex hormones remain low despite treatment, your doctor may recommend Hormone Replacement Therapy (HRT) (such as a testosterone gel or estrogen patch) to help protect your bones. For severe osteoporosis, specific bone-building medications like bisphosphonates might also be prescribed.
What You Can Do Today
While medical treatments do the heavy lifting in addressing the hormonal imbalance, you can actively support your bone recovery through daily lifestyle choices:
- Ensure adequate intake of Calcium and Vitamin D, which are the building blocks of healthy bone. Ask your doctor if you should have your Vitamin D levels checked.
- Engage in weight-bearing exercises (like walking, jogging, or resistance training), which stimulate your bones to grow stronger.
Common questions in this guide
Do I need a DEXA scan if I have a prolactinoma?
How does a prolactinoma cause osteoporosis?
Can the bone loss from a prolactinoma be reversed?
Why are men with prolactinomas at a higher risk for bone loss?
Will I need hormone replacement therapy for my bones?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given how long I've experienced symptoms of low sex hormones, should I schedule a baseline DEXA scan to check my bone density?
- 2.If my dopamine agonist medication takes a long time to normalize my prolactin, should we consider temporary hormone replacement therapy to protect my bones?
- 3.Should we check my Vitamin D and calcium levels to make sure my body has what it needs to rebuild bone?
- 4.If my DEXA scan shows osteopenia or osteoporosis, what timeline should we set for a follow-up scan?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (20)
- 1
Interpretation of Serum Gonadotropin Levels in Hyperprolactinaemia.
Abbara A, Clarke SA, Nesbitt A, et al.
Neuroendocrinology 2018; (107(2)):105-113 doi:10.1159/000489264.
PMID: 29660734 - 2
Unraveling the Cycle: A Scoping Review Exploring the Impact of Antidepressants on the Female Reproductive Cycle.
Weatherly S, Garazi CD, Woldenberg E, et al.
Cureus 2025; (17(11)):e97360 doi:10.7759/cureus.97360.
PMID: 41426913 - 3
[Prolactinoma causing erectile dysfunction].
Muadi J, Sánchez A
Revista internacional de andrologia 2021; (19(4)):285-288 doi:10.1016/j.androl.2020.05.003.
PMID: 33358454 - 4
Persistent bone impairment despite long-term control of hyperprolactinemia and hypogonadism in men and women with prolactinomas.
Andereggen L, Frey J, Andres RH, et al.
Scientific reports 2021; (11(1)):5122 doi:10.1038/s41598-021-84606-x.
PMID: 33664388 - 5
Hyperprolactinemia Due to Prolactinoma has an Adverse Impact on Bone Health with Predominant Impact on Trabecular Bone: A Systematic Review and Meta-Analysis.
Nagendra L, Dutta D, Mondal S, et al.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(1)):101453 doi:10.1016/j.jocd.2023.101453.
PMID: 38064881 - 6
Characterization of bone disease in cystic fibrosis.
Contreras-Bolívar V, Andreo-López MC, Muñoz-Torres M
Medicina clinica 2025; (164(1)):23-29 doi:10.1016/j.medcli.2024.05.014.
PMID: 39019666 - 7
Assessing Bone Mineral Density Using Radiographs of the Hand: A Multicenter Validation.
Burton H, Bodansky D, Silver N, et al.
The Journal of hand surgery 2023; (48(12)):1210-1216 doi:10.1016/j.jhsa.2023.08.009.
PMID: 37737801 - 8
Drug-induced Hyperprolactinemia Results in Atypical Atypical Fracture.
Lee I, Son DW, Park JH, Park JH
Hip & pelvis 2021; (33(2)):102-107 doi:10.5371/hp.2021.33.2.102.
PMID: 34141697 - 9
Prolactinoma: A Massive Effect on Bone Mineral Density in a Young Patient.
Sperling S, Bhatt H
Case reports in endocrinology 2016; (2016()):6312621 doi:10.1155/2016/6312621.
PMID: 27446618 - 10
Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia.
Montejo ÁL, Arango C, Bernardo M, et al.
Revista de psiquiatria y salud mental 2016; (9(3)):158-73.
PMID: 26927534 - 11
Adult Dual-Energy X-ray Absorptiometry in Clinical Practice: How I Report it.
Messina C, Sconfienza LM, Bandirali M, et al.
Seminars in musculoskeletal radiology 2016; (20(3)):246-253 doi:10.1055/s-0036-1592370.
PMID: 27741540 - 12
Nonalcoholic Fatty Liver Disease, Bone and Muscle Quality in Prolactinoma: A Pilot Study.
Eroğlu İ, Iremli BG, Erkoc A, et al.
Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry 2024; (27(2)):101479 doi:10.1016/j.jocd.2024.101479.
PMID: 38447349 - 13
Hypopituitarism in patients with prolactinomas: a narrative review.
Campana C, Patelli I, Arecco A, et al.
Best practice & research. Clinical endocrinology & metabolism 2026; 102082 doi:10.1016/j.beem.2026.102082.
PMID: 41638953 - 14
[Guidelines of the Chilean Endocrinology Society for the correct clinical use of bone densitometry].
Barberán M M, Campusano M C, Trincado M P, et al.
Revista medica de Chile 2018; (146(12)):1471-1480 doi:10.4067/s0034-98872018001201471.
PMID: 30848752 - 15
Characteristics and outcomes of men with erectile dysfunction as the presenting symptom due to a lactotroph adenoma.
Andereggen L, Tortora A, Schubert GA, et al.
Acta neurochirurgica 2024; (166(1)):314 doi:10.1007/s00701-024-06213-9.
PMID: 39085672 - 16
Treatment of hyperprolactinaemia reduces total cholesterol and LDL in patients with prolactinomas.
Schwetz V, Librizzi R, Trummer C, et al.
Metabolic brain disease 2017; (32(1)):155-161 doi:10.1007/s11011-016-9882-2.
PMID: 27525431 - 17
The effect of bromocriptine treatment on sexual functioning and depressive symptoms in women with mild hyperprolactinemia.
Krysiak R, Szkróbka W, Okopień B
Pharmacological reports : PR 2018; (70(2)):227-232 doi:10.1016/j.pharep.2017.10.008.
PMID: 29475005 - 18
Is There a Role for Hormonal Therapy in Men with Oligoasthenoteratozoospermia (OAT)?
Çayan S, Altay AB, Rambhatla A, et al.
Journal of clinical medicine 2024; (14(1)) doi:10.3390/jcm14010185.
PMID: 39797269 - 19
Follow-up of hypogonadotropic hypogonadism recovery in Chinese male prolactinoma patients treated with dopamine agonists.
Zhang Y, Li Y, Cui Q, et al.
Endocrine 2025; (90(3)):1438-1445 doi:10.1007/s12020-025-04433-2.
PMID: 40974505 - 20
Different Cabergoline Effect on Metabolic and Anthropometric Parameters in Female Prolactinoma Patients Versus Idiopathic Hyperprolactinemia Patients.
Aboelnaga MM, Eladawy EH, Elshafei MM, et al.
Endocrine, metabolic & immune disorders drug targets 2019; (19(4)):511-518 doi:10.2174/1871530319666190219103812.
PMID: 30806330
This page is for informational purposes only and does not replace professional medical advice. Always consult your endocrinologist or healthcare provider about your specific bone health, DEXA scan needs, and treatment plan.
Get notified when new evidence is published on Prolactinoma.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.